Event context and recent performance

Abbott Laboratories (ABT) has been drawing investor attention after a period where the stock has delivered a one month return of about a 2% decline and a past 3 months return of roughly a 13% decline.

Against this backdrop, the company’s current share price near $109.95, a recent one day gain of about 2%, and mixed longer term total returns are prompting closer scrutiny of how its diversified healthcare business and earnings profile line up with today’s valuation.

Over the past year, Abbott’s share price has trended lower with a year to date share price return of an 11.47% decline and a 1 year total shareholder return of a 12.24% decline. This contrasts with a 19.16% gain over three years, suggesting longer term holders have still seen a positive outcome even as recent momentum has faded.

If you are assessing how this shift in sentiment around healthcare and diagnostics fits into your portfolio, it can be useful to compare Abbott with other healthcare related AI names using the 33 healthcare AI stocks

With Abbott posting annual revenue of about US$44.3b, net income of roughly US$6.5b, and trading near US$109.95 with an indicated discount to some intrinsic estimates, the key question is whether there is a genuine opportunity here or if the market already reflects its future growth potential.

Most Popular Narrative: 3.5% Undervalued

According to the most followed narrative, Abbott’s fair value sits close to $113.88, slightly above the recent $109.95 close. This frames the current pullback as a modest discount rather than a deep bargain.

Abbott Laboratories is a compelling growth investment with defensive qualities, supported by its market leadership, innovation-driven strategy, and diversified portfolio. While its premium valuation may limit near-term upside, the company’s strong fundamentals, exposure to high-growth markets, and commitment to shareholder returns make it a solid choice for investors with a medium- to long-term horizon. Strategic entry points and careful monitoring of growth drivers and market dynamics will be key to maximizing returns.

Curious what underpins that fair value number. The narrative leans on consistent revenue growth, firm profit margins, and an earnings profile that supports a higher multiple for a healthcare name.

Result: Fair Value of $113.88 (UNDERVALUED)

However, this story can change quickly if key products face stronger competition, or if regulatory decisions hit margins and challenge that 3.5% undervalued case.

Next Steps

Given the mix of caution and optimism in this story, it helps to look at the numbers yourself and decide quickly where you stand using the 4 key rewards and 1 important warning sign

Looking for more investment ideas?

If Abbott does not fully fit what you want, consider broadening your watchlist so you do not miss other opportunities that may better suit your style.

• Target potential mispricings by scanning companies that currently look attractively priced using the 47 high quality undervalued stocks.
• Strengthen your income stream by focusing on companies offering higher yields and resilient payouts with the 15 dividend fortresses.
• Prioritize capital preservation by filtering for companies that carry lower risk profiles through the 74 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.